Long Acting Peptide Modification Patents: Who Leads, Where Gaps Are 2026
Long Acting Peptide Modification Patents: Concentration at the Top, Room at the Edges
62.7% of all 765 records sit with just five assignees, so most of the core lipidation and albumin-binding claim space is already staked out by a small group. Annual filings peaked in 2017 at 104 and have since settled lower; the 2021 to 2024 span — the last window unaffected by publication lag — still rose from 39 to 45 filings, a +15% increase. Years after 2024 will fill in further as applications publish, so treat the most recent bars as a floor, not a ceiling.
- 1BIOVERATIV THERAPEUTICS INC135
- 2ZEALAND PHARMA AS109
- 3NOVO NORDISK AS103
- 4BRISTOL MYERS SQUIBB CO82
- 5NOVO NORDISK HEALTH CARE AG51
See the full long acting peptide modification analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in long acting peptide modification?
One assignee leads with 135 records in this dataset, well ahead of the fifth-place holder at 51 and the tenth-place holder at 27. The top five assignees together account for 62.7% of all 765 records in scope, and the top ten account for 83.9%. This is a leader-plus-long-tail structure: a small number of companies hold most of the claim space, with 68 companies in total appearing in the ranked list.
Is patent filing in this field growing or slowing down?
Filing peaked in 2017 at 104 records and has not returned to that level since, but that does not mean the field is slowing. The 2021-to-2024 window, the most recent period unaffected by publication lag, shows filings rising from 39 to 45, a 15% increase. Figures for 2025 and 2026 will keep filling in as pending applications publish, so any apparent recent drop should not yet be read as a real decline.
What technology areas dominate long acting peptide modification patents?
Medicinal preparation claims under A61K cover 83.1% of the 765 records, and peptide/protein composition claims under C07K cover 54.4% — the two dominant classes by a wide margin. Therapeutic activity claims (A61P) reach 41.0%, while genetic engineering (C12N) sits at 16.5%. Because a single record can carry several IPC classes, these shares add up to more than 100%, which is expected.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Long Acting Peptide Modification covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.